Oscar Nominated Actor Eric Roberts to Be New Spokesman for Genmed’s Generic Drug Global Market Expansion

Actor Endorses Drug Company’s Goal to Distribute Low Cost Generics Worldwide

HOLLYWOOD--(BUSINESS WIRE)-- Academy Award nominated actor Eric Roberts turns to drugs in a positive way by becoming the spokesperson for pharmaceutical licensing company, Genmed Holding Corp. (OTCBB: GENM). Endorsing the good work of the Dutch/US based company, Roberts will act as spokesman for the company and its efforts to advance the cause of bringing high quality generic drugs to corners of the world that have, until now, gone without the most basic of medications.

Roberts brings very real, personal experiences to Genmed that helped him through his own health crises. The actor’s highly publicized history of drug dependency, humbly revealed to the world recently on the VH1 reality show “Celebrity Rehab,” does not make him the most likely candidate to speak on behalf of a leading edge drug company like Genmed, but the company felt strongly that Roberts, who struggles with an acute anxiety disorder, is someone who can express firsthand the positive impact that vitally needed medications can have on one’s health, family and quality of life.

“I’ve had my own health scares in life including the car accident that left me in a coma for three days,” said Roberts. “Under those circumstances, you become acutely aware of the need for even the most basic of safe, well-tested, properly prescribed medications to help you to recover and to be comfortable while doing it. I embrace the mission of an innovative company like Genmed that is working to bring current and soon-to-be- released generic medications to virtually billions of people around the world who have never benefitted from products that are so basic to our own well being in developed countries.”

Genmed currently works to bring 69 FDA quality A approved low cost generics to non EU countries. Governmental pressures and new insurance policies in many countries are rapidly increasing the necessity for these low cost generics that share the same active ingredients, dose to treat the same disease, in an equally safe and effective delivery medium as their reference medicines.

Genmed is also in the process of registering, distributing and marketing 17 of these generic products in 12 EU countries in the next three years, starting with the products with the highest sale value. Genmed calculates that the current sales volume for their target markets, both in the EU and developing countries, is approximately 9.4 billion Euros.

If you are interested in learning more about this innovative company, please reference their stock symbol GENM or visit the Genmed website at www.genmed.nl.

About Genmed Holding Corp.

Genmed Holding Corp. is a fully reporting publicly traded company that trades on the OTC under the symbol GENM. It is a United States and Dutch based company focusing on the delivery of low cost generic pharmaceutical drugs directly to distribution channels throughout the world. The Company began its generic drug business in 2008 and today operates primarily through its 100% owned subsidiary Genmed B.V., which is registered in the Netherlands. The Company is led by an experienced management team and board who have considerable and highly relevant experience in product development, registration, sales, marketing, distribution, operations, and financial administration.

For Additional Information, Go to the Website: www.genmed.nl

This press release contains certain "forward-looking statements" within the meaning of federal securities laws including the use of the words "expect," "anticipate," "estimate," "project," "forecast," "outlook," "target," "objective," "plan," "goal," "pursue," "on track," and similar expressions. Although the Company believes that the statements were reasonable when made, these forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied. The Company assumes no obligation and does not intend to update these forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: competitive and general economic conditions, adverse effects of litigation, the timely development and acceptance of our products and services, significant changes in the competitive environment, the failure to generate or the loss of significant numbers of customers, the loss of senior management or increased government regulations.

Scripted ConsultingBill Schlueter, 310-397-4321

Source: Genmed Holding Corp.